Stasys Medical, a startup spun out of research done at the University of Washington, has raised a Series A funding round led by the W Fund with participation from WRF Capital. The financial terms of the deal were not disclosed.
The new funding will give Stasys additional resources to complete development of a device designed to detect blood clot dysfunction from trauma, also known as trauma-induced coagulopathy (TIC). TIC impairs blood’s ability to clot, occurs in more than 1 in 4 severely injured patients and increases the risk of death five-fold. Stasys’s device will allow emergency physicians to determine in minutes whether a patient has TIC and respond accordingly.
“Currently available tests to determine if a trauma patient has TIC take too long,” UW Emergency Medicine physician and Stasys co-founder Nathan White said in a press release. “The Stasys device holds the promise of reducing mortality and morbidity by rapidly determining if a patient has TIC.”
Prior to this raise, Stasys brought in more than $1.5 million in grants from a variety of sources including DARPA, the National Science Foundation, the Coulter Foundation and UW’s CoMotion.
It’ll be a while before Stasys’s device hits the market, though: the company said it plans to launch the device in 2018.
